Clinical trial
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
NCT00327249 · AmpliMed Corporation, Industry · Completed
Key facts
| NCT number | NCT00327249 |
|---|---|
| Title | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients |
| Official title | A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma |
| Lead sponsor | AmpliMed Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | imexon |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | May 18, 2006 |
| Last update posted | Aug 11, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: